Highlights from

WCD 2019

World Congress of Dermatology

Milan 10-15 June 2019

Letter from the Editor

Dear Colleagues,

The 24th World Congress of Dermatology is the worldwide congress with participation of more than 14,000 delegates. Over 150 sessions were organised covering 43 topic areas. Delegates attended from more than 140 countries.

In this Medicom Conference Report you can find a selection of information across Dermatology. Perhaps the most important development in Dermatology is translational research, with impact on patient care. Also important are new drug developments and selection of treatments based on stratification of patient groups with clinical characteristics and biomarkers.

In psoriasis, there is a knowledge revolution on treatment selection based on clinical aspects and endotype and therapeutic revolution with the availability of targeted therapies. Availability of biosimilars with price reductions of TNF-alpha inhibitors has opened opportunities for prescribing biologics in underserved areas of the world. In particular in atopic dermatitis and hidradenitis chronica suppurativa, similar developments in innovation in personalised treatment and targeted therapies in inflammatory dermatoses can be seen. An important area is lupus erythematosus: Insights in the lupus complex are developing rapidly and new therapeutic approaches are available. It is important for dermatologists to follow these developments.

Not only in inflammatory dermatoses but also in oncology important innovations in targeted therapies and treatment selection based on molecular characteristics of the malignancies are developing rapidly, with clear advances in the management of melanoma. Current medications used in oncology may have cutaneous side effect and prevention of such side effects by EGFR inhibitors. What to do in case of cutaneous side effects to checkpoint inhibitors can be found in this review.

In daily practice, the management of keloids is a frequent problem. In this review some new aspects will be highlighted.

Biologics have opened the door for drug development of small molecules, which can be given as oral drugs and in the future as topicals if the molecular weight is sufficiently low. For diseases such as vitiligo and alopecia areata these developments have resulted in new therapeutic leads.

What is a congress without posters? A wealth of innovation was presented by presenters from all over the world. In this review you find some interesting communications.

Prof. dr Peter CM van de Kerkhof Senior Professor of Dermatology Radboud University Nijmegen Medical Center The Netherlands

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.